PE20091078A1 - Formulacion inyectable para ocrelizumab (2h7) - Google Patents

Formulacion inyectable para ocrelizumab (2h7)

Info

Publication number
PE20091078A1
PE20091078A1 PE2008001653A PE2008001653A PE20091078A1 PE 20091078 A1 PE20091078 A1 PE 20091078A1 PE 2008001653 A PE2008001653 A PE 2008001653A PE 2008001653 A PE2008001653 A PE 2008001653A PE 20091078 A1 PE20091078 A1 PE 20091078A1
Authority
PE
Peru
Prior art keywords
antibody
seq
injectable formulation
ocrelizumab
full length
Prior art date
Application number
PE2008001653A
Other languages
English (en)
Inventor
David Robert Close
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE20091078A1 publication Critical patent/PE20091078A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

REFERIDA A UN ANTICUERPO DE CD20 HUMANIZADO, QUIMERICO O HUMANO, DONDE EL ANTICUERPO HUMANIZADO SE SELECCIONA DEL GRUPO FORMADO POR LAS VARIANTES 2H7 A, B E I QUE CONTIENEN UNA CADENA L DE LONGITUD COMPLETA DE SEQ ID NO: 6 Y UNA CADENA LARGA DE LONGITUD COMPLETA DE SEQ ID NO: 7, 8 Y 15, O UN FRAGMENTO DE LAS MISMAS; EL ANTICUERPO QUIMERICO ES RITUXIMAB. TAMBIEN ESTA REFERIDA A UNA COMBINACION DEL ANTICUERPO CD20 CON UN FARMACO TAL COMO ETANERCEPT, INFLIXIMAB, METOTREXATO, OFATUMUMAB, CICLOFOSFAMIDA, ENTRE OTROS Y A UNA FORMULACION INYECTABLE. DICHOS ANTICUERPOS SON UTILES EN EL TRATAMIENTO DE ENFERMEDADES AUTOINMUNES, INCLUIDA LA ARTRITIS REUMATOIDE
PE2008001653A 2007-09-24 2008-09-22 Formulacion inyectable para ocrelizumab (2h7) PE20091078A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US97464107P 2007-09-24 2007-09-24
GBGB0718684.4A GB0718684D0 (en) 2007-09-24 2007-09-24 Treatment method

Publications (1)

Publication Number Publication Date
PE20091078A1 true PE20091078A1 (es) 2009-07-23

Family

ID=38670460

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008001653A PE20091078A1 (es) 2007-09-24 2008-09-22 Formulacion inyectable para ocrelizumab (2h7)

Country Status (10)

Country Link
EP (1) EP2197916A1 (es)
JP (1) JP2011501734A (es)
CN (1) CN101809036A (es)
AR (1) AR068531A1 (es)
CA (1) CA2700351A1 (es)
CL (1) CL2008002817A1 (es)
GB (1) GB0718684D0 (es)
PE (1) PE20091078A1 (es)
TW (1) TW200918091A (es)
WO (1) WO2009040268A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9296820B2 (en) 2003-11-05 2016-03-29 Roche Glycart Ag Polynucleotides encoding anti-CD20 antigen binding molecules with increased Fc receptor binding affinity and effector function
AR073295A1 (es) 2008-09-16 2010-10-28 Genentech Inc Metodos para tratar la esclerosis multiple progresiva. articulo de fabricacion.
IL293708B2 (en) * 2015-10-06 2026-04-01 Genentech Inc A method for treating multiple sclerosis
CA3016880A1 (en) * 2016-03-07 2017-09-14 Sanofi Biotechnology Compositions and methods for treating rheumatoid arthritis
IL272418B2 (en) * 2017-08-08 2024-09-01 Hoffmann La Roche Abinotuzumab treatment of a new subgroup of DLBCL patients
US20210317220A1 (en) * 2018-09-24 2021-10-14 Janssen Biotech, Inc. Method of providing safe administration of an anti-cd154 antibody
JP7848114B2 (ja) * 2019-10-12 2026-04-20 バイオ－セラ ソリューションズ リミテッド 抗ｃｄ２０抗体製剤及びｃｄ２０陽性疾患の治療のための抗ｃｄ２０抗体の使用
TW202337494A (zh) 2021-11-16 2023-10-01 美商建南德克公司 用莫蘇妥珠單抗治療全身性紅斑狼瘡（ｓｌｅ）之方法及組成物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI335821B (en) * 2002-12-16 2011-01-11 Genentech Inc Immunoglobulin variants and uses thereof
TW200637574A (en) * 2005-01-13 2006-11-01 Genentech Inc Treatment method
RU2421242C2 (ru) * 2005-07-25 2011-06-20 Трабьон Фармасьютикалз, Инк. Применение однократной дозы cd20-специфических связывающих молекул
MY149159A (en) * 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage

Also Published As

Publication number Publication date
CA2700351A1 (en) 2009-04-02
TW200918091A (en) 2009-05-01
GB0718684D0 (en) 2007-10-31
JP2011501734A (ja) 2011-01-13
CL2008002817A1 (es) 2009-10-16
WO2009040268A1 (en) 2009-04-02
CN101809036A (zh) 2010-08-18
EP2197916A1 (en) 2010-06-23
AR068531A1 (es) 2009-11-18

Similar Documents

Publication Publication Date Title
PE20091078A1 (es) Formulacion inyectable para ocrelizumab (2h7)
PE20120899A1 (es) Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c3b
NL301196I2 (nl) inebilizumab
AR124676A2 (es) Formulación farmacéutica que comprende una droga biofarmacéutica
CO6260105A2 (es) Anticuerpos humanos contra cd20 humano y metodo para utilizarlos
PE20200011A1 (es) ANTICUERPOS ANTI-PEPTIDO BETA AMILOIDE N3pGlu Y SUS USOS
AR081434A1 (es) Anticuerpo del peptido relacionado con el gen calcitonina (cgrp), composicion farmaceutica que lo comprende, uso de dicho anticuerpo para preparar un medicamento util para tratar dolor de osteoartritis o migranas y fragmento de union a antigeno de dicho anticuerpo
PE20180502A1 (es) Composiciones anti-cgrp y uso de las mismas
PE20141432A1 (es) Anticuerpos neutralizantes de citomegalovirus humano
PE20120427A1 (es) Anticuerpos contra el receptor de cgrp humano
PE20120816A1 (es) Composiciones que comprenden anticuerpos de dickkopf-1
PE20130817A1 (es) Anticuerpos peptidicos beta amiloide anti-n3pglu y usos de los mismos
PE20091197A1 (es) ANTAGONISTAS Bv8 COMO INHIBIDORES DE ANGIOGENESIS
PE20110802A1 (es) Un anticuerpo antagonista de pcsk9
PE20181054A1 (es) Anticuerpos anti-cd19 humano humanizados y metodos de utilizacion
PE20121563A1 (es) Anticuerpos que se unen especificamente al receptor epha2
PE20081478A1 (es) Anticuerpos cd44
PE20120205A1 (es) Combinaciones antitumorales que contienen anticuerpos que reconocen especificamente cd38 y citarabina
ES2572177T3 (es) Anticuerpos neutralizantes anti-B7RP1 humanos
PE20180249A1 (es) Anticuerpos neutralizadores anti-ccl20
PE20140247A1 (es) Anticuerpos anti-cd38
PE20140806A1 (es) Anticuerpos anti-factor d humanizados y sus usos
PE20160652A1 (es) Anticuerpos que se unen a il-17f
PE20200695A1 (es) Anticuerpos que reconocen tau
PE20190261A1 (es) Anticuerpos que reconocen tau

Legal Events

Date Code Title Description
FD Application declared void or lapsed